Disease or Syndrome – Page 93

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###

11 months ago talkbio0Tagged Alexion, amgen, Approved, AstraZeneca, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hemolytic-Uremic Syndrome, Infrequent, interchangeable, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals

Amgen Secures FDA Approval for Bkemv, the First Interchangeable Biosimilar to Soliris for Rare Blood Disorders

11 months ago talkbio0Tagged amgen, Approved, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hematological Disease, Hemolytic-Uremic Syndrome, Infrequent, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

FDA approval, Amgen, Bkemv, Soliris, biosimilar, rare blood disorders, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)

AstraZeneca’s Oral PCSK9 Inhibitor AZD0780 Demonstrates Significant LDL-C Reduction in Phase 1 Trial

11 months ago talkbio0Tagged Administration of prophylactic statin, AstraZeneca, AZD0780, Cardiovascular Diseases, cholesterol, Hypercholesterolemia, PCSK9 Inhibitor [EPC], phase 1 trial

PCSK9 inhibitor, AZD0780, AstraZeneca, cholesterol reduction, phase 1 trial, statin therapy, hypercholesterolemia, cardiovascular disease

Asahi Kasei Acquires Calliditas Therapeutics for $1.1 Billion to Expand in Rare Disease Market

11 months ago talkbio0Tagged Acquisition (action), Asahi Kasei, Calliditas, IGA Glomerulonephritis, Kidney Diseases, Market, pharmaceutical growth strategy, Tarpeyo

Asahi Kasei, Calliditas Therapeutics, acquisition, rare disease market, kidney disease, Tarpeyo, IgA nephropathy, pharmaceutical growth strategy

Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis

11 months ago talkbio0Tagged Biological Factors, Center for Drug Evaluation, Chronic small plaque psoriasis, Class, drug application, Innovent, Interleukin-23 Subunit p19, Moderate (severity modifier), National Medical Product Administration, Phase III CLEAR-1 Study, picankibart

Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.